The KLOW stack
GLOW plus KPV.
Follow the evidenceAll 3 sources
FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory CommitteeSecondary sourceFDA Panel Votes to Loosen Restrictions for Four PeptidesSecondary sourceFDA Peptide Update 2026: Removal from the Do Not Compound List
A linked source is not a clinical endorsement. How we handle review and corrections.
What's in it
Why people combine them
KPV is added for its anti-inflammatory effect in lab studies, on top of the repair and skin pieces in GLOW.
The honest part
When the FDA reviewed KPV this year, it found no data on KPV given to people by any route. Add the stability question that comes with copper in a mixed vial, and KLOW is the stack we'd be slowest to recommend.
How Goodmorrow does it
- Topical GHK-Cu now. BPC-157 and TB-500 separately once lawful. KPV only if your clinician has a specific reason.
What you can do today
Topical GHK-Cu is available when we open.
Questions people ask
KLOW or Wolverine?
If both become lawful, start with the simpler one. Adding compounds with no human data doesn't make a stack better.
Sources
- FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
- Secondary sourceFDA Panel Votes to Loosen Restrictions for Four Peptides PharmExec, July 2026
- Secondary sourceFDA Peptide Update 2026: Removal from the Do Not Compound List Frier Levitt, August 2026
Good days ahead.
Join the opening list for appointment updates.